Please assess the completion status of the following clinical trial:

Trial Title: Naloxegol Health Outcome Post Authorisation Safety Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Patient receives a new prescription for naloxegol or a non-PAMORA laxative. (Note: Only non-PAMORA laxatives that are approved/marketed in the European Union at the time naloxegol is authorized are permitted.)~Exclusion Criteria:~1. Patients \<18 years of age on cohort entry date~2. Patients with \<1 year of continuous data available prior to cohort entry date~3. Patients without exposure to current regular opioid use defined by \>30 days of opioid exposure within the 180 days prior to and inclusive of the cohort entry date~4. Patients with evidence of a cancer indicator (diagnosis or treatment) prior to cohort entry date~5. Exposure to PAMORA laxatives, alvimopan, methylnaltrexone, or naloxone + opioid combination (including fixed-dose combinations) prior to cohort entry date

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- naloxegol (Type: None): patients exposed to naloxegol
- non-PAMORA laxative (Type: None): patient exposed to non-peripherally acting mu-opioid receptor antagonist (PAMORA) laxative

Based on this trial design, predict the completion outcome and termination type (if applicable).